Cultural and economic influences on the psychopharmacological era are reviewed, in an attempt to bring into focus what has been happening in psychopharmacology for the past thirty years. It is argued that the belief that clinical advances are made through the heroic achievements of disinterested scientists is a simplistic view that may militate against future significant discoveries. Such discoveries, it is argued, still come about for the most part serendipitously, despite a widespread belief that psychopharmacology has become a rational science.
Get full access to this article
View all access options for this article.
References
1.
Amdisen A.1984Lithium treatment of mania and depression over one hundred years, in Current Trends in Lithium and Rubidium Therapy, ed Corsini G U. MTP Press, Lancaster, 11-26
2.
Ayd F.J., Blackwell B.1970Discoveries in biological psychiatry, Lippincott, Philadelphia.
3.
Baumann P., Jonzier-Perey M., Koeb L., Le P.K., Tinguely D., Schopf J.1986Amitriptyline pharmacokinetics and clinical response: 1 free and total plasma amitriptyline and nortriptylineInt Clin Psychopharmacol1: 89-101
4.
Baldessarim R.1980Drugs used in the treatment of the psychoses, in The pharmacological basis of therapeutics, eds Gilman A G, Goodman L S, Gilman A. Basingstoke, Macmillan, 395-418
5.
Barrow N., Childs A.1986Anti-tardive-dyskmesia effect of verapamilAm J Psychiat143: 1485
Cantopher T., Edwards J.G., Olivieri S.1988The government, the pharmaceutical industry and the economics of psychotropic drug prescribingHuman Psychopharmacol3: 289-300
12.
Capstick N.1971Chlorimipramine in obsessional statesPsychosomatics12: 332
13.
Capstick N.1973The Graylingwell StudyJ Int Med Res1: 392-396
14.
Carlsson A.1982Rationale and design of a selective inhibitor of 5HT reuptakeBrit J Clin Pract (Symp Suppl) 19: 19-22
15.
Carney M W P, Sheffield B.F.1975Forty-two months experience of flupenthixol decanoate in the maintenance treatment of schizophreniaCurr Med Res Opin3: 447-452
16.
Cocarro E.F., Siever L.J.1985The second generation of antidepressants: a comparative reviewJ Clin Psychopharmacol25: 241-260
17.
Cordoba E.F., Lopez-Ibor J.J.1967Monochlorimipramine in psychiatric patients resistant to other forms of treatmentActas Luso-espanolas Neurol Psiquiat26: 119-147
18.
Cowdry R.W., Gardner D.L.1988Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, tranylcypromineArch Gen Psychiat45: 111-119
Davies D.L., Shepherd M.1955Reserpine in the treatment of anxious and depressed patientsLancetii: 117-120
21.
Davies D.M.1981Textbook of adverse drug reactions, Oxford University Press, Oxford, 226-227
22.
De Montigny C., Chaput Y., Blier P.1988Lithium augmentation of antidepressant treatments: evidence for the involvement of the 5HT system? in New concepts in depression eds Briley M, Fillion G. Macmillan Press, Basingstoke144-160
23.
Dinan T.G., Capstick C.1989A pilot study of verapamil in the treatment of tardive dyskinesiaHum Psychopharmacol4: 55-58
24.
Dukes M.N.1988Meyler's side effects of drugs, Elsevier , Amsterdam
25.
Fahy T.J.1989Depression in general practice: the Newcastle connection, in contemporary themes in psychiatry, eds Davison K, Kerr A, Gaskell Publications, Alden Press, Oxford
26.
Frolund F.1974Treatment of depression in general practice; a controlled trial of flupenthixol (Fluanxol)Curr Med Res Opin2: 78-89
27.
Gardner M.J., Altman D.G.1986Confidence intervals rather than P values: estimation rather than hypothesis testingBrit Med J292: 746-750
28.
Girard M., Biscos-Garreau M.1989Reliability of data on haematotoxicity of antidepressants: a retrospective assessment of haematological monitoring in clinical studies on tricyclicsJ Affect Disord17: 153-158
29.
Goodman W.K., Price L.H., Rasmussen S.A., Delgado P.L., Hemnger G.R., Charney D.S.1989Efficacy of fluvoxamine in obsessesive-compulsive disorderArch Gen Psychiat46: 36-44
30.
Guyotat J., Favre-Tissot M., Marie-Gardine M.1968A clinical trial with a new antidepressant G 34586. Congress de psychiatrie et de neurologie, Dijon 1967, 717, Masson , Paris
31.
Hamilton M.1967Development of a rating scale for primary depressive illnessBrit J Soc Clin Psychol6: 278-296
32.
Healy D.1987a The structure of psychopharmacological revolutionsPsychiat Dev5: 349-376
33.
Healy D.1987b The comparative psychopathology of affective disorders in animals and humansJ Psychopharmacol1: 193-210
34.
Healy D.1989Neuroleptics and psychic indifferenceJ Roy Soc Med82: 615-619
35.
Healy D., Williams J M G1989Moods, misattributions and maniaPsychiatric Dev7: 49-70
Healy D.1990b The suspended revolution: psychiatry and psychotherapy re-examinedFaber and Faber Ltd, London
38.
Holmberg M.B., Jansson B.1962A study of blood count and serum transaminase in prolonged treatment with amitritylineJ New Drugs2: 361-365
39.
Johnson D A W1979A double-blind comparison of flupenthixol, nortriptyline and diazepam in neurotic depressionActa Psychiat Scand59: 1-8
40.
Johnson D A W, Malik N.A.1975A double-blind comparison of fluphenazine decanoate and flupenthixol decanoate in the treatment of acute schizophreniaActa Psychiat Scand51: 257-267
41.
Johnson F.N.1984The history of lithium therapyMacmillan , London
42.
Kalinowsky L.B., Hoch P.H.1961Somatic treatment in psychiatryGrune and Stratton, New York
43.
Katz R., Landau P.L., Moroz G., DeVeaugh-Geiss J.1988Obsessive-compulsive rituals. Brit J Psychiat153: 845
44.
Kelly D., Guirguis W., Frommer E., Mitchell-Heggs N., Sargant W.1970Treatment of phobic states with antidepressants: a retrospective study of 246 patientsBrit J Psychiat116: 387-398
45.
Klerman G.L., Cole J.O.1965Clinical pharmacology of imipramine and related compoundsPharmacol Rev17: 101-141
46.
Klerman G.L., Ballenger J.C., Burrows G.D., DuPont R.L., Noyes R., Pecknold J.C., Rifkm Q.A., Rubin R.T., Swinson R.P.1989In reply to Marks et al. Arch Gen Psychiat46: 670-672
47.
Kline N.S.1954Use of reserpine serpentina benth in neuropsychiatric conditionsAnn N Y Acad Sci59: 107-132
48.
Kuhn R.1970The imipramine story, in Discoveries in biological psychiatry , eds Ayd F J, Blackwell B, Lippincott, Philadelphia205-217
49.
Kuhn R.1990Artistic imagination and the discovery of antidepressantsJ Psychopharmacol4(3): 00-00
50.
Leonard B.E.1984Pharmacology of new antidepressantsProg Neuro Psychopharmacol Biol Psychiat8: 97-108
51.
Liebenau J.1987Medical science and medical industry, Macmillan Press, Basingstoke
52.
Liebowitz M.R., Klein D.F.1979Hysteroid dysphoriaPsychiat Clin N Amer2: 555-575
53.
McKeown T.1979The role of medicine, Basil Blackwell , Oxford
54.
McNair D.M., Rizley R., Kahn R.J.1986Amoxapine and speed of onset: new antidepressant faces old methodologyJ Clin Psychiat Mono, 4: 18-22
55.
Marks I.M.1989The gap between research and policy in mental health careJ Roy Soc Med82: 514-517
56.
Marks I.M., Stern R.S., Mawson D., Cobb J., McDonald R.1980Clomipramine and exposure for obsessive-compulsive ritualsBrit J Psychiat136: 1-25
57.
Marks I.M., Lelliott P., Basoglu M., Noshirvani H., Monteiro W., Cohen D., Kasvikis Y.1988Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive ritualsBrit J Psychiat152: 522-534
58.
Marks I., Basoglu M.1989Obsessive-compulsive ritualsBrit J Psychiat154: 565-567
59.
Marks I., O'Sullivan G.1988Drugs and psychological treatments for agoraphobia/panic and obsessive-compulsive disorders: a reviewBrit J Psychiat153: 650-658
60.
Marks I.M., De Albuquerque A., Cotteaux J., Gentil V., Greist J., Hand I., Liberman R.L., Relvas J.S., Tobena A., Tyrer P., Wittchen H-U.1989The efficacy of alprazolam in panic-disorder and agoraphobia: a critique of recent reportsArch Gen Psychiat46: 668-670
61.
Marshall W.K., Micev V.1973Clomipramine (Anafranil) in the treatment of obsessional illnesses and phobic anxiety statesJ Int Med Res: 403-412
62.
May P.R., Van Putten T., Yale C.1976Predicting individual responses to drug treatment in schizophrenia: a test dose modelJ Nerv Ment Dis162: 177-183
63.
Medical Research Centre Trial1965Clinical trial of the treatment of depressive illnessBrit Med Ji: 881-886
64.
Merton R.K.1968The Matthew effect in scienceScience159: 56-63
65.
Merton R.K.1969Behaviour patterns of scientistsAm Sci57: 1-23
66.
Moller H.J., Meier K., Wernicke T.1988Empiricial investigation on the risk of agranulocytosis/leucopenia under medication with antidepressantsPharmacopsychiatry21: 304-305
67.
Montgomery S.A., James D., De Ruiter M., Egglestone J., Hawley C., Birkett P., Baldwin D., Chu C., Montgomery D.1986Weekly oral fluoxetine treatment of major depressive disorder15th CINP, Puerto Rico
68.
Office of Population Censuses and Surveys1977-1984. Mortality statistics: accidents and violence. Series DH4, Table 10. Deaths from poisoning by solid or liquid substancesHMSO, London
69.
O'Sullivan G., Marks I.1990Long-term outcome of phobic and obsessive-compulsive disorders after treatment, in Handbook of anxiety disorders, eds Noyes R et al, Elsevier Press, Amsterdam
70.
Ovhed I.1976A double-blind study of flupenthixol (Fluanxol) in general practiceCurr Med Res Opin4: 144
71.
Pare C M B1985The present status of monoamine-oxidase inhibitorsBrit J Psychiat146: 576-584
72.
Parnham M.J., Bruinvels J.1983Discoveries in pharmacology. vol 1 Psycho and neuropharmacology , Elsevier Press, Amsterdam
73.
Paykel E.S., Parker R.R., Rowan P.R., Rao B.M., Taylor C.N.1983Nosology of atypical depressionPsychol Med13: 131-139
74.
Paykel E.S.1989Antidepressants: their efficacy and place in therapyJ Psychopharmacol2: 105-118
75.
Pinder R.1988The benefits and risks of antidepressant drugsHuman Psychopharmacol3: 73-86
76.
Pollitt J., Young J.1971Anxiety state or masked depression? A study based on the action of monoamine oxidase inhibitorsBrit J Psychiat119: 143-149
77.
Pollock B.G., Perel J.M., Nathan S., Kupfer D.J.1989Acute antidepressant effect following pulse loading with intravenous and oral clomipramineArch Gen Psychiat46: 29-35
78.
Porter R., Porter D.1989The rise of the English drugs industry: the role of Thomas CorbynMed Hist33: 277-295
79.
Predescu V., Ciurezu T., Timofte G., Roman I.1973Symptomatic relief with flupenthixol (Fluanxol) of the anxiousalgetic-depressive syndrome complex in neurotic statesActa Psychiat Scand49: 15-27
80.
Rack P.H.1973Clomipramine (Anafranil) in the treatment of obsessional states with special reference to the Leyton Obsessional InventoryJ Int Med Res1: 397-402
81.
Razak1983Flupenthixol versus phenelzine in the treatment of neurotic depression: a double-blind trial cited in Robertson and Trimble as in press
82.
Reiter P.J.1969On flupenthixol, an antidepressant of a new chemical groupBrit J Psychiat115: 1399-1402
83.
Rickels K., Feighner J.P., Smith W.T.1985Alprazolam, amitriptyline, doxepin and placebo in the treatment of depressionArch Gen Psychiat42: 134-141
84.
Robertson M.M., Trimble M.R.1982Major tranquillisers used as antidepressantsJ Affect Disord4: 173-193
85.
Rosenberg I.U., Ostensen A.I., Fonnelo H.1976Flupenthixol-nortriptyline in the treatment of patients with anxiety-depression-astheniaTidssk Nor Laegeforen96: 229-233
86.
Sandler M.1990The discovery of monoamine oxidase inhibitors : history and mythologyJ Psychopharmacol4(3): 00-00
Sireling L.I., Paykel E.S., Freeling P., Rao R.M., Patel S.P.1985Depression in general practice: case thresholds and diagnosisBrit J Psychiat147: 113-119
91.
Sonne I M1966Flupenthixol (fluanxol) in the treatment of depressive statesNord Psychiat Tidssk20: 322-324
Sulser F., Mishra R.1983The discovery of tricyclic antidepressants and their mode of action, in Discoveries m Pharmacology vol 1, Psycho and neuropharmacology , eds Parnham M J, Bruinvels J, Elsevier Press, Amsterdam, 233-247
94.
Swazey J.P.1974Chlorpromazine and psychiatryMIT Press , Cambridge, Mass
95.
Symes M.H.1967. Monochlorimipramine: a controlled trial of a new antidepressantBrit J Psychiat113: 671-672
96.
Tiller J., Schweitzer I., Maguire K., Davies B.1989Is diazepam an antidepressant?Brit J Psychiat155: 483-489
Waddington J.L.1989Implications of recent research on dopamine D 1 and D2 receptor subtypes in relation to schizophrenia and neuroleptic drug actionCurr Opin Psychiat2: 89-92
99.
Waddington J.L., O'Boyle K.M.1989Drugs acting on brain dopamine receptors: a conceptual re-evaluation 5 years after the first selective D1 antagonistPharmacol Ther43: 1-52
100.
Walter C J S1973Clinical impressions on treatment of obsessional states with intravenous clomipramine (anafranil)J Int Med Res1: 413-416
101.
Waxman D.1973A general practitioner investigation on the use of clomipramine (anafranil) in obsessional and phobic disordersJ Int Med Res1: 417-420
102.
West E.D., Dally P.J. (1959) Effects of iproniazid in depressive syndromesBrit Med J1: 1491-1499
103.
Whalley L.J.1989Drug treatments of dementiaBrit J Psychiat155: 595-611
104.
Young J P R, Hughes W.C., Lader M.H.1976A controlled comparison of flupenthixol and amitripytline in depressed out-patientsBrit Med Ji: 1116-1118
105.
Zis A.P., Goodwin F.K.1982The amine hypothesis, in Handbook of the affective disorders , ed Paykel, E S. Churchill-Livingstone, Edinburgh175-190.
106.
Zohar J., Insel T.R., Zohar-Kadouch R.C., Mueller E.A., Murphy D.L.1989Serotonergic challenges before and after treatment in obsessive-compulsive disorderJ Psychopharmacol Proc Summer Meeting of Brit Assoc for Psychopharmacology